亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Survival Outcomes in Patients With Hormone Receptor–Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy

医学 肿瘤科 内科学 乳腺癌 转移性乳腺癌 雌激素受体 癌症 曲妥珠单抗 激素受体 免疫组织化学 队列 激素疗法
作者
Jason Mouabbi,Akshara Singareeka Raghavendra,Roland L. Bassett,Amy Hassan,Debasish Tripathy,Rachel M. Layman
出处
期刊:JAMA network open [American Medical Association]
卷期号:6 (5): e2313017-e2313017 被引量:20
标识
DOI:10.1001/jamanetworkopen.2023.13017
摘要

Importance Approximately 45% to 60% of hormone receptor (HR)–positive metastatic breast cancer (mBC) shows a low-level expression of ERBB2 . Low ERBB2 expression is defined as ERBB2 immunohistochemical expression of 1+ or 2+ with a negative ERBB2 amplification by in situ hybridization. The efficacy of the antibody-drug conjugate trastuzumab deruxtecan in low- ERBB2 , HR-positive mBC has been practice changing. However, there are conflicting data on the prognostic value of low ERBB2 expression in HR-positive mBC and whether low ERBB2 expression is a separate entity. Objective To examine whether outcomes differ by immunohistochemical analysis for patients with HR-positive mBC with low ERBB2 expression vs those without ERBB2 expression when treated with targeted therapy (TT) plus endocrine therapy (ET). Design, Setting, and Participants This single-institution cohort study used prospectively collected electronic data from the MD Anderson Cancer Center for patients with a diagnosis of HR-positive mBC treated with ET in combination with a TT (cyclin-dependent kinase 4/6 inhibitors [CDK4/6is], everolimus, or alpelisib) between January 1, 2010, and December 31, 2021. Exposure HR-positive mBC with either low or no ERBB2 expression. Main Outcome and Measures The main outcomes were median progression-free survival and overall survival. Data on demographic characteristics, estrogen and progesterone receptor status, ERBB2 status, histologic subtype, menopausal status, treatment duration, and survival status were collected. Results A total of 1585 women (median [range] age, 51 [24-92] years) were included in the study. Of these women, 1013 (63.9%) had mBC with low ERBB2 expression and 572 (36.1%) had mBC with no ERBB2 expression. A total of 1084 (68.4%) were treated with a CDK4/6i (912 patients were treated in the first line and 172 were treated in the second line); 475 (30.0%) received everolimus and 26 (1.6%) received alpelisib. In the patients who received a first-line CDK4/6i, 618 (67.8%) received an aromatase inhibitor as their ET backbone and 265 (29.1%) received fulvestrant. With a median follow-up time of 17.9 months (range, 1-111 months), progression-free survival and overall survival were not statistically different between the patients with low and no ERBB2 expression treated with TT plus ET. Conclusions and Relevance In this cohort study of patients with HR-positive mBC treated with TT plus ET, low ERBB2 expression did not have a significant association with prognosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
8秒前
抚琴祛魅完成签到 ,获得积分10
10秒前
复杂月饼完成签到,获得积分10
10秒前
11秒前
sugar发布了新的文献求助10
13秒前
科目三的应助被sugar采纳,获得10
20秒前
29秒前
FIGGIEKIO发布了新的文献求助10
36秒前
41秒前
科研通AI65的应助被冰凌采纳,获得10
42秒前
大模型的应助被甜甜的小土豆采纳,获得10
43秒前
50秒前
52秒前
可爱的函函的应助被专注凌柏采纳,获得10
52秒前
黄志伟完成签到,获得积分20
53秒前
黄志伟发布了新的文献求助10
56秒前
万能图书馆的应助被冰凌采纳,获得10
58秒前
超帅的半莲完成签到,获得积分10
1分钟前
1分钟前
Caiyuping完成签到 ,获得积分10
1分钟前
星辰大海的应助被花痴的文涛采纳,获得10
1分钟前
魔幻芷巧发布了新的文献求助10
1分钟前
ay完成签到 ,获得积分10
1分钟前
科研通AI6.3的应助被冰凌采纳,获得10
1分钟前
1分钟前
smsk完成签到,获得积分20
1分钟前
1分钟前
wanci的应助被科研通管家采纳,获得10
1分钟前
执着的秋柳完成签到,获得积分10
1分钟前
Orange的应助被科研通管家采纳,获得10
1分钟前
gAle完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
iuiu666完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195028
求助须知:如何正确求助?哪些是违规求助? 9580770
关于积分的说明 21872653
捐赠科研通 7794788
什么是DOI,文献DOI怎么找? 3437886
关于科研通互助平台的介绍 2561176
邀请新用户注册赠送积分活动 2484562